ZVSA
ZyVersa Therapeutics, Inc.
OTCHealthcareBiotechnologyUS
Rating:C
Company Profile
CEO
Stephen C. Glover
IPO Date
2022-02-11
Sector
Healthcare
Industry
Biotechnology
Exchange
OTC
Country
US
ZyVersa Therapeutics, Inc.
CEO
Stephen C. Glover
IPO Date
2022-02-11
Sector
Healthcare
Industry
Biotechnology
Exchange
OTC
Country
US
| 11,066 |
| $0.59 |
| 15 Jul 2025 | Glover Stephen C. | director, officer: Chief Executive Officer | A-Award | Acquired | 136,900 | $0.59 |
| 15 Jul 2025 | Finizio Robert G | director | A-Award | Acquired | 11,066 | $0.59 |
| 15 Jul 2025 | Wolfe Peter | Chief Financial Officer | A-Award | Acquired | 60,100 | $0.59 |
| 15 Jul 2025 | Guzman Pablo A. | Chief Medical Officer | A-Award | Acquired | 48,900 | $0.59 |
| 15 Jul 2025 | Park Min-Chul | director | A-Award | Acquired | 11,066 | $0.59 |
| 15 Jul 2025 | SAPIRSTEIN JAMES | director | A-Award | Acquired | 11,066 | $0.59 |
| 18 Jul 2024 | SAPIRSTEIN JAMES | director | A-Award | Acquired | 132 | $152.46 |
| 18 Jul 2024 | Finizio Robert G | director | A-Award | Acquired | 132 | $152.46 |